Do you know what share of STVN GLP-1 exposure (~20% of rev) is from NOVO vs LILLY? Is STVN the main partner of LILLY? And what share of historic STVN growth has been driven by GLP-1s vs Biologics growth? - these are my main questions - you have any insight?
They don't disclose either so impossible to know, but it does seem evident that a significantly higher share of future growth will come from biologics (they've hinted at this) which was not the case historically
Solid quarter and still a 30% gap down, feels like a restaurant fully booked except the one table that ordered half the menu just cancelled, the GLP-1 concentration is the real story.
Adding while you feel like puking is usually the honest version of buying a drop, so respect for writing that down.What would you need to see in March to admit the add was wrong? - because by then, the story will sound good either way.
Non-GLP biologics up over 30% in the quarter is the part I'd hang onto, and Fishers breaking even at gross profit with only ~50% of capacity installed leaves a lot of operating leverage on the table. Do you think the 2027 air pocket is mostly one syringe program, or wider than that?
Do you know what share of STVN GLP-1 exposure (~20% of rev) is from NOVO vs LILLY? Is STVN the main partner of LILLY? And what share of historic STVN growth has been driven by GLP-1s vs Biologics growth? - these are my main questions - you have any insight?
They don't disclose either so impossible to know, but it does seem evident that a significantly higher share of future growth will come from biologics (they've hinted at this) which was not the case historically
Solid quarter and still a 30% gap down, feels like a restaurant fully booked except the one table that ordered half the menu just cancelled, the GLP-1 concentration is the real story.
I've had so many "I felt like puking" situations this year, but they typically are the best ones in hindsight if our research was right.
Edenred at 16 felt like a punch in the gut. Innoscripta too lately (jury still out if doubling down was smart or not).
STVN is compelling to add the shared back I sold over $20, but there are also so many other cheap stocks right now.
Adding while you feel like puking is usually the honest version of buying a drop, so respect for writing that down.What would you need to see in March to admit the add was wrong? - because by then, the story will sound good either way.
Non-GLP biologics up over 30% in the quarter is the part I'd hang onto, and Fishers breaking even at gross profit with only ~50% of capacity installed leaves a lot of operating leverage on the table. Do you think the 2027 air pocket is mostly one syringe program, or wider than that?